Novel Immunotherapies for Osteosarcoma
Osteosarcoma (OS) is the most common primary malignant bone sarcoma mainly affecting adolescents and young adults, which often progresses to pulmonary metastasis and leads to the death of OS patients. OS is characterized as a highly heterogeneous cancer type and the underlying pathologic mechanisms...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.830546/full |
| _version_ | 1828309680290529280 |
|---|---|
| author | Yubao Lu Jiahe Zhang Yutong Chen Yuchen Kang Zhipeng Liao Yuanqi He Cangyu Zhang |
| author_facet | Yubao Lu Jiahe Zhang Yutong Chen Yuchen Kang Zhipeng Liao Yuanqi He Cangyu Zhang |
| author_sort | Yubao Lu |
| collection | DOAJ |
| description | Osteosarcoma (OS) is the most common primary malignant bone sarcoma mainly affecting adolescents and young adults, which often progresses to pulmonary metastasis and leads to the death of OS patients. OS is characterized as a highly heterogeneous cancer type and the underlying pathologic mechanisms triggering tumor progress and metastasis are incompletely recognized. Surgery combined with neoadjuvant and postoperative chemotherapy has elevated 5-year survival to over 70% for patients with localized OS tumors, as opposed to only 20% of patients with recurrence and/or metastasis. Therefore, novel therapeutic strategies are needed to overcome the drawbacks of conventional treatments. Immunotherapy is gaining momentum for the treatment of OS with an increasing number of FDA-approved therapies for malignancies resistant to conventional therapies. Here, we review the OS tumor microenvironment and appraise the promising immunotherapies available in the management of OS. |
| first_indexed | 2024-04-13T15:32:23Z |
| format | Article |
| id | doaj.art-8c68afb6ffb54315a86a3e1145d6936c |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T15:32:23Z |
| publishDate | 2022-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-8c68afb6ffb54315a86a3e1145d6936c2022-12-22T02:41:21ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-04-011210.3389/fonc.2022.830546830546Novel Immunotherapies for OsteosarcomaYubao Lu0Jiahe Zhang1Yutong Chen2Yuchen Kang3Zhipeng Liao4Yuanqi He5Cangyu Zhang6Department of Spine Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, ChinaThe Second Clinical Medical College, Lanzhou University, Lanzhou, ChinaThe Second Clinical Medical College, Lanzhou University, Lanzhou, ChinaThe Second Clinical Medical College, Lanzhou University, Lanzhou, ChinaThe Second Clinical Medical College, Lanzhou University, Lanzhou, ChinaThe Second Clinical Medical College, Lanzhou University, Lanzhou, ChinaDepartment of Orthopaedics, Lanzhou University Second Hospital, Lanzhou, ChinaOsteosarcoma (OS) is the most common primary malignant bone sarcoma mainly affecting adolescents and young adults, which often progresses to pulmonary metastasis and leads to the death of OS patients. OS is characterized as a highly heterogeneous cancer type and the underlying pathologic mechanisms triggering tumor progress and metastasis are incompletely recognized. Surgery combined with neoadjuvant and postoperative chemotherapy has elevated 5-year survival to over 70% for patients with localized OS tumors, as opposed to only 20% of patients with recurrence and/or metastasis. Therefore, novel therapeutic strategies are needed to overcome the drawbacks of conventional treatments. Immunotherapy is gaining momentum for the treatment of OS with an increasing number of FDA-approved therapies for malignancies resistant to conventional therapies. Here, we review the OS tumor microenvironment and appraise the promising immunotherapies available in the management of OS.https://www.frontiersin.org/articles/10.3389/fonc.2022.830546/fullimmunotherapiesosteosarcomaimmune microenvironmentPD-1CAR TTCR T |
| spellingShingle | Yubao Lu Jiahe Zhang Yutong Chen Yuchen Kang Zhipeng Liao Yuanqi He Cangyu Zhang Novel Immunotherapies for Osteosarcoma Frontiers in Oncology immunotherapies osteosarcoma immune microenvironment PD-1 CAR T TCR T |
| title | Novel Immunotherapies for Osteosarcoma |
| title_full | Novel Immunotherapies for Osteosarcoma |
| title_fullStr | Novel Immunotherapies for Osteosarcoma |
| title_full_unstemmed | Novel Immunotherapies for Osteosarcoma |
| title_short | Novel Immunotherapies for Osteosarcoma |
| title_sort | novel immunotherapies for osteosarcoma |
| topic | immunotherapies osteosarcoma immune microenvironment PD-1 CAR T TCR T |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.830546/full |
| work_keys_str_mv | AT yubaolu novelimmunotherapiesforosteosarcoma AT jiahezhang novelimmunotherapiesforosteosarcoma AT yutongchen novelimmunotherapiesforosteosarcoma AT yuchenkang novelimmunotherapiesforosteosarcoma AT zhipengliao novelimmunotherapiesforosteosarcoma AT yuanqihe novelimmunotherapiesforosteosarcoma AT cangyuzhang novelimmunotherapiesforosteosarcoma |